ライフサイエンスコーパス: mean survival time

1 nces in 60-month life expectancy (restricted mean survival time).

2 es in the RCTs were compared with restricted mean survival time.

3 Survival was assessed with restricted mean survival time.

4 ctional regression model, and the restricted mean survival time.

5 ibed masses and yielded a 30% enhancement in mean survival time.

6 the liver and kidney, and a 20% reduction in mean survival time.

7 e-care facility was associated with a longer mean survival time.

8 iology (ASA) score (difference in restricted mean survival time 0.12 years [95% CI 0.07-0.16; P < 0.0

9 rejected when transplanted into BALB/c mice (mean survival time: 10+/-0.8 days), normal C57BL/6 mice

10 ificantly prolonged in TLR4(-/-) recipients (mean survival time=10.6 and 14.3 days, respectively).

11 fully MHC-mismatched DBA/2 skin allografts (mean survival time, 12 days; n = 6) compared with the wi

12 transplants was more rapid than skin grafts (mean survival time, 12.9 vs. 26.6 days), and islet graft

13 me: 16.5+/-2.1 days) as well as CD8-KO mice (mean survival time: 12.8+/-1.3 days).

14 n = 8) as compared with wild-type controls (mean survival time 13 +/- 4, n = 7).

15 WT patients (5-year difference in restricted mean survival times, 13.6 months; P < .001).

16 ype and markedly slower disease progression (mean survival time 14 years).

17 e showed significantly (P < 0.005) shortened mean survival time (16.2 +/- 5.3 months) compared to the

18 l time: 10+/-0.8 days), normal C57BL/6 mice (mean survival time: 16.5+/-2.1 days) as well as CD8-KO m

19 n the vitamin K antagonist group (restricted mean survival time, 1608 days vs. 1680 days; difference,

20 grafts were vigorously rejected by DKO mice (mean survival time 17 +/- 7, n = 8) as compared with wil

21 acute rejection of class I-disparate hearts (mean survival time, 19+/-7.21 vs. 38+/-8.19; P=0.025) bu

22 , >120 days), but not in CD8-deficient mice (mean survival time, 20 days).

23 erved with either weekly regimen (restricted mean survival time 24.4 months [97.5% CI 23.0-26.0] in g

24 sion who underwent resection of cancer had a mean survival time 25.5 months shorter than that of pati

25 ival of the kidney capsule islet xenografts (mean survival time = 26.5 +/- 7.8 days vs. 15.2 +/- 5.3

26 red to mice that received irradiation alone (mean survival time, 31 days; P=0.001).

27 who received chemotherapy alone (restricted mean survival time 34.5 months [95% CI 32.0-37.0] with s

28 6) recipients survived significantly longer (mean survival time, 38 +/- 8 days) compared with those t

29 efit of bevacizumab was recorded (restricted mean survival time 44.6 months [95% CI 43.2-45.9] in the

30 diated (600 rads), naive C57BL/6 recipients (mean survival time = 48.9 +/- 17.1 days), and three of t

31 n unimmunized cyclosporine-treated controls (mean survival time = 5.5 +/-1.7 vs. 54.7 +/-3.8 days, P

32 b group after 3 years (P = 0.005; Restricted Mean Survival Time = 5.9 months, 95% CI = 1.4-10.4 month

33 raft rejection compared with untreated mice (mean survival time: 54 vs. 8 days, P < 0.0001).

34 RCCs, and all grew progressively but slowly (mean survival times, 57 to >100 days) in vivo after intr

35 n group (difference calculated as restricted mean survival time, 7.4 days; 95% confidence interval [C

36 100 days, n=2) and rejection of third-party (mean survival time: 7.5+/-0.5 days, n=2) hearts.

37 f CsA (1.0 mg/kg/day) alone was ineffective (mean survival time=7.0+/-0.7 vs. 6.4+/-0.6 days in treat

38 chemotherapy alone (difference in restricted mean survival time, 72 days; 95% confidence interval, 36

39 n = 6) compared with the wild-type controls (mean survival time, 8 days; n = 7).

40 grafts were rejected by C57Bl/6 recipients (mean survival time=8.2 and 9.3 days, respectively), graf

41 Mean survival time among animals treated with saline or

42 Mean survival time among hemoadsorption-treated animals

43 ged group (95% CI, -63 to 7 days; restricted mean survival time analysis).

44 was analyzed using nonparametric restricted mean survival time analysis.

45 Restricted mean survival time and life-years lost were calculated a

46 te liver failure significantly prolonged the mean survival time and resolved the liver injury when co

47 Withdrawal significantly decreased the mean survival time and significantly increased the Salmo

48 tom resolution were calculated as restricted mean survival times and accounted for censored observati

49 rtant difference in revision-free restricted mean survival time, and a reduced relative risk of reope

50 to oral infection, as assessed by survival, mean survival time, and colony culture.

51 evidenced by increased mortality, shortened mean survival time, and increased bacterial load in the

52 ve incidences, cause-specific HR, restricted mean survival time, and life-years lost at 10 and 20 yea

53 overall survival, risk of death, restricted mean survival time, and palliative care, hospice, and ac

54 model, a milestone analysis, and restricted mean survival time are examined.

55 ort study assesses the utility of restricted mean survival time as a method for quantifying time to n

56 rds, so we used the difference in restricted mean survival time as the primary estimate of effect.

57 ffect and introduce difference in restricted mean survival times as an alternative to identify faster

58 whiB3 mutant strain had significantly longer mean survival times as compared with mice challenged wit

59 ed paclitaxel benefits in terms of increased mean survival time, as well as median survival time.

60 proportional hazard analysis with restricted mean survival time at 36 months.

61 Compared with immediate initiation, the mean survival time at 7 years with a strategy of initiat

62 as the difference in the 36-month restricted mean survival time between 2 conventional survival end p

63 how no demonstrable difference in restricted mean survival time between groups after 13.9 years (P =

64 The difference in restricted mean survival time between groups was 53 days (95% CI 28

65 teins that are clinically diverse, producing mean survival times between 2 and 12 years (postdiagnosi

66 expectancy was calculated as the restricted mean survival time (bound by the maximum follow-up of 20

67 accination with YpkA significantly prolonged mean survival time but did not increase overall survival

68 Overall, LIMK1/2 suppression increased mean survival time by 30%.

69 time to hospital, analysed using restricted mean survival time, Cox proportional hazards, and flexib

70 r, in non-high-risk patients, the restricted mean survival time did not differ significantly between

71 The restricted-mean survival time difference (RMST-D) and restricted-me

72 The restricted mean survival time difference favored TEVAR at 9 years,

73 an unexposed facilities (adjusted restricted mean survival time difference, 91.2 days [95% CI, 30.6-1

74 The mean survival time difference/ratio is an intuitive, ass

75 isk differences, risk ratios, and restricted mean survival time differences were estimated from inver

76 The difference in restricted mean survival time (dRMST) test is frequently proposed a

77 higher survival rate (75% versus 62.5%) and mean survival time during the first 21 days postchalleng

78 Mean survival time for grafts incubated in F(ab')2 anti-

79 the estimated mean difference in restricted mean survival time for grafts that experienced a DSAEK i

80 d the simulation reproduces the experimental mean survival times for all four sites with activation e

81 Likewise, mean survival times for B6 skin grafts placed on C.B6-(n

82 The mean survival times for the treated and control groups w

83 The mean survival time free from death was 1101.48 (95% CI,

84 Also, sunitinib reduced mean survival times from 12 to 6 days in virus-infected

85 l of Balb/c KTx in naive C57BL/6 recipients (mean survival time >100 days vs. 52 days in controls; P<

86 lantation induced indefinite graft survival (mean survival time >140.3+/-12.3 vs. 12.7+/-0.7 control,

87 en rats were treated with FK506 monotherapy (mean survival time >60 days, n=4).

88 in allograft survival in CD4-deficient mice (mean survival time, >120 days), but not in CD8-deficient

89 st treatment in wild-type mice increased the mean survival time in response to CLP.

90 Mean survival time in the fully MHC-mismatched skin graf

91 Estimated mean survival time in the Kaplan-Meier analysis was 147

92 Mean survival time is extended from 5-7.5 weeks for cont

93 commonly observed, making cure or restricted mean survival time models preferable for analysis of ICI

94 al hazards frailty regression and restricted mean survival time models were fitted using reconstructe

95 -term survival of Lewis pancreas xenografts (mean survival time (MST) >90 days).

96 Untreated control rats had a mean survival time (MST) +/- SE of 27 +/- 1 day, and irr

97 controls, 0.5 mg/kg SRL per day extended the mean survival time (MST) from 6.4+/-0.5 days to 12.3+/-3

98 ivo, 20 mg/kg 17359 prolonged survivals to a mean survival time (MST) of 18.3+/-2.6 days (P<0.001) in

99 In the ACI to Lewis combination, the mean survival time (MST) of the untreated group was 5.2

100 e incidence as wild-type control mice, their mean survival time (MST) was significantly longer than t

101 SL model demonstrated significantly improved mean survival time (MST) with single fraction whole-brai

102 sis, The incidence of graft rejection, graft mean survival time (MST), and alloimmune responses, and

103 In comparison to untreated recipients (mean survival time (MST): 5.3 +/- 0.5 days), anti-CD134L

104 ng renal allograft acceptance: the BMT/renal mean survival time (MST, 76 days) was not significantly

105 n a long-term survival of kidney allografts (mean survival time [MST] > 100.0 days, n=5).

106 heart graft rejection both in the B10-->C3H (mean survival time [MST] 7.8+/-0.2 days; control MST 10.

107 n rapid fashion either LEW heart allografts (mean survival time [MST] = 4.2+/-0.4 days vs. 5.6+/-0.5

108 nsplants of islets from BALB/c into C57BL/6 (mean survival time [MST]: 16.5 vs. 12.0 days; P = 0.004)

109 l of hamster liver xenografts in Lewis rats (mean survival time [MST]=10.5 days, n=6, and MST=9.0 day

110 The mean survival times (MSTs) of RG2 glioma bearing rats we

111 rafts in Lewis (LEW; RT1l) recipients from a mean survival time of 10.6 +/- 1.9 days in untreated con

112 loss of contractility, and ecchymosis and a mean survival time of 12.5 +/- 6.4 min.

113 tely rejected C57BL/10 islet allografts at a mean survival time of 13.8 +/- 2.7 days (n=5).

114 allograft survival (>200 days) compared to a mean survival time of 15.0+/-2.3 days in controls treate

115 reas xenografts were acutely rejected with a mean survival time of 15.3 days in B cell-deficient mice

116 4 days, whereas tumor-bearing controls had a mean survival time of 16 +/- 2 days.

117 The six Linplant implant animals had a mean survival time of 164 days (range, 1-264 days), a "l

118 largement, and severe kidney failure, with a mean survival time of 2 months.

119 hazards was seen (p=0.037), with restricted mean survival time of 23.9 months (97.5% CI 22.1-25.6) i

120 val to 30 days was 81.7% (1349/1651), with a mean survival time of 26.5 days (95% CI 26.1-26.9) with

121 RL(lpr) mice had prolonged viability, with a mean survival time of 33.0 wk compared with 22.6 wk in c

122 antation of tumor (1 x 10(5) cells) showed a mean survival time of 35 +/- 4 days, whereas tumor-beari

123 ontrast, tacrolimus + donor BM resulted in a mean survival time of 42 days (P<0.01 compared with tacr

124 able dementia with a reduction in restricted mean survival time of 44.9 days.

125 ) for frailty with a reduction in restricted mean survival time of 48.8 days and 2.18 (95% CI, 1.40-3

126 Patients receiving beta-blockers had a mean survival time of 5.1 months compared to 6 months fo

127 ed with the control regimen (no DBM) with an mean survival time of 53 days (P=0.022).

128 ed on exogenous protamine zinc insulin had a mean survival time of 53 days (range, 10-217), a "last e

129 nated mice challenged with yeast cells had a mean survival time of 56 days, compared with <13 days fo

130 nts with none of the adverse genotypes had a mean survival time of 62.1 months, and those with one, t

131 he grafts in this model were rejected with a mean survival time of 7+/-1 days and showed extensive ev

132 rejected Lewis (RT1l) kidney allografts at a mean survival time of 8.5+/-1.1 days.

133 ents acutely rejected kidney allografts at a mean survival time of 8.8 +/- 0.75 d.

134 istar-Furth (WF; RT1u) heart allografts at a mean survival time of 8.9+/-1.0 days.

135 d to 56 days, 8.0 mg/kg/q.o.d BQR produced a mean survival time of 83.8 +/0 33.8 days (P < 0.001), wi

136 reater prolongation of graft survival with a mean survival time of 88 days compared with the control

137 ly prolonged Lewis cardiac allografts from a mean survival time of 9.8+/-0.7 days in controls to 19.8

138 (Emu) develop B-cell lymphoma and exhibit a mean survival time of approximately 6 months.

139 The mean survival time of BALB/c islet allografts transplant

140 icrovessel density as well as with decreased mean survival time of HCC patients.

141 l fibrosing interstitial lung disease with a mean survival time of less than 5 years.

142 une response that significantly improved the mean survival time of mice bearing established lung meta

143 onger tumor growth suppression and increased mean survival time of the mice compared with the treatme

144 p = 0.006)." Kaplan-Meier analysis revealed mean survival times of 9.3 years for PR and 12.65 years

145 ghly correlated with the previously reported mean survival times of animals treated with the same age

146 GDNF significantly prolonged mean survival times of Hol(Tg/Tg) mice, Ednrb(s-l//s-l)

147 Kidney CFU and mean survival times of infected mice pretreated with MAb

148 The restricted mean survival time offers a robust alternative to the ha

149 creased in the docetaxel arm (the restricted mean survival time over 10 years was 9.11 v 8.82 years;

150 nd to determine the corresponding restricted mean survival time over a 15-year period.

151 pared with control groups, with </=29.2 days mean survival time (P < 0.001).

152 (95% CI, 1.9-16.9 months; P = .008) shorter mean survival time restricted after 12.5 years compared

153 th (95% CI, 2.2-18.3 months; P = .02) longer mean survival time restricted at 15 years compared with

154 Moreover, reverse restricted mean survival time (RMST) analysis of overall survival u

155 of post hoc analyses have applied restricted mean survival time (RMST) analysis on the aggregated-lev

156 death was assessed using adjusted restricted mean survival time (RMST) analysis.

157 Overal survival (OS) according to restricted mean survival time (RMST) and median OS, and hazard rati

158 fects of interest were the 7-year restricted mean survival time (RMST) differences between intensive

159 ate or enzalutamide and evaluated restricted mean survival time (RMST) differences in overall surviva

160 cular outcomes, while calculating restricted mean survival time (RMST) for each outcome.

161 The restricted mean survival time (RMST) has been advocated as an alter

162 Restricted mean survival time (RMST) is a useful summary measuremen

163 h death as a competing event, and restricted mean survival time (RMST) model were used to analyze the

164 Restricted mean survival time (RMST) quantifies risk into the time

165 The restricted mean survival time (RMST) was 18 months longer (95% CI,

166 rved nonproportional hazards; the restricted mean survival time (RMST) was 6.81 years for 3 years of

167 Restricted mean survival time (RMST) was used to compare OS and PFS

168 val, which was measured using the restricted mean survival time (RMST) with propensity score adjustme

169 One-year FRI rate, restricted mean survival time (RMST), and adjusted hazard ratio (aH

170 y end point was the difference in restricted mean survival time (RMST).

171 by the difference (and ratio) of restricted mean survival times (RMST) in oncology randomized trials

172 hazard ratio (aHR) of death, and restricted mean survival times (RMST) were analyzed as of September

173 ival over an 8-year time horizon (restricted mean survival time [RMST]) for each combination of clini

174 P < 0.001, test for difference in restricted mean survival time [RMST]), but no differences were obse

175 survival were compared using the restricted mean survival times (RMSTs) across different age and soc

176 We computed 1-, 3-, and 5-year restricted mean survival times (RMSTs) from adjusted Cox models.

177 y two distinct quantities) of the restricted mean survival times (RMSTs, expectation of life at a giv

178 Despite reducing FV3 loads and extending the mean survival time, rXlIFN treatments failed to prevent

179 Mean survival time (+/-SEM) in animals treated with MMF

180 Mean survival time (+/- standard error of mean) in anima

181 had a significantly higher survival rate and mean survival time than mice immunized with only LVS Del

182 lliation failure had a significantly shorter mean survival time than those without complications (14.

183 death and of death or AIDS-defining illness, mean survival time, the proportion of individuals in nee

184 pient, and eye bank variables and restricted mean survival time through 47 months (1434 days) after D

185 transplantation prolonged cardiac allograft mean survival time to >120 days compared with untreated

186 transplantation prolonged cardiac allograft mean survival time to 25.7+/-0.9 days compared with untr

187 plantation was able to extend the Pd grafts' mean survival time to 32 months for fourteen 4 Pd grafts

188 f SRL with 0.5 mg/kg/day FTY720 extended the mean survival time to 34.4+/-8.8 days (CI=0.28).

189 is such as milestone survival, or restricted mean survival time to capture the value of indolent HCC.

190 with deficiencies, differences in restricted mean survival time to reinspection were evaluated.

191 10-year area under the curve; ie, restricted mean survival time) to emulate a randomized clinical tri

192 significantly protected, as reflected by the mean survival time versus control grafts (27+/-20 days [

193 The overall (n = 242) mean survival time was 10.9 (95% CI 9.9-11.9) years.

194 The mean survival time was 118 months in low Met expression

195 The mean survival time was 12.8 years for qualified success

196 The mean survival time was 14.2 months (range, 2.1-33.1 mont

197 nts with tumors that responded to treatment, mean survival time was 15 months (range, 4.5-33.1 months

198 The restricted mean survival time was 1599 days in the rivaroxaban grou

199 The mean survival time was 74.4 days (SEM 6.39 days) in sali

200 The mean survival time was 8 years; however, 5 patients died

201 The difference in restricted mean survival time was 8.00 months (99.9% CI, 4.94 to 11

202 At 10-year follow-up, the restricted mean survival time was 8.6 months (or 12.1%) longer in t

203 Within 1 year, the restricted mean survival time was longer with EPNs in all (12 days;

204 No difference in mean survival time was seen in low-to-moderate-risk and

205 Finally, mean survival time was significantly longer (720 vs. 381

206 Differences in mean survival time were observed with increasing social

207 Mean survival times were 6.9 years for the continuation

208 Mean survival time, which was 51 mins in the control gro

209 The mean survival time with the Kaplan-Mayer analysis was 10

210 Life expectancy was estimated by restricted mean survival time within 10 years, and QOL status accor